Embolization of iliac metastasis during lenvatinib treatment in patient with advanced Hurthle cell thyroid carcinoma

被引：2

作者：

Rodia, Rossella ^{[1
,2
]}

Marini, Stefano ^{[3
]}

Pani, Fabiana ^{[1
,4
]}

Boi, Francesco ^{[1
,2
]}

Mariotti, Stefano ^{[1
,2
]}

机构：

[1] Univ Cagliari, Postgrad Sch Endocrinol & Metab Dis, Dept Med Sci & Publ Hlth, Cagliari, Italy

[2] AOU Monserrato, Endocrinol Unit Duilio Casula Hosp, Cagliari, Italy

[3] ASSL Cagliari, SS Trinita Hosp, Dept Radiol, Cagliari, Italy

[4] Johns Hopkins Sch Med, Div Immunol, Dept Pathol, Ross Res Bldg,Room 656,720 Rutland Ave, Baltimore, MD 21205 USA

来源：

FUTURE ONCOLOGY | 2019年 / 15卷 / 24S期

关键词：

antiangiogenic treatment; embolization; lenvatinib; metastatic thyroid cancer; patient safety; TYROSINE-KINASE INHIBITORS; MULTIKINASE INHIBITORS; HEMORRHAGIC EVENTS; FLARE-UP; CANCER; GROWTH; ANGIOGENESIS; SORAFENIB; THERAPIES; RISK;

D O I：

10.2217/fon-2019-0184

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lenvatinib is a tyrosine kinase inhibitor (TKI) with antiproliferative and antiangiogenic effects indicated for the treatment of progressive, locally advanced or metastatic progressive thyroid carcinoma, refractory to radioactive iodine therapy. Antiangiogenic therapies induce ischemic necrosis of tumor tissue, with increased risk of hemorrhagic complications. The management of hemorrhagic risk is based on precautionary measures and for any surgical procedure, it is advised to interrupt the treatment in order to avoid complications. 'Flare-up' of tumor activity may follow TKI interruption. However, it is not known if continuing TKIs during minimally invasive interventions is safe. We report here the first case in which an embolization of metastasis is performed without interrupting lenvatinib treatment. The procedure was successful and free of complications.

引用

页码：35 / 40

页数：6

共 25 条

[1] Anti-angiogenic therapies and hemorrhagic risk [J].

Ayllon, J. ;

Pignot, G. .

PROGRES EN UROLOGIE, 2010, 20 :S20-S22

[2] Timing of multikinase inhibitor initiation in differentiated thyroid cancer [J].

Brose, Marcia S. ;

Smit, Johannes ;

Lin, Chia-Chi ;

Pitoia, Fabian ;

Fellous, Marc ;

DeSanctis, Yoriko ;

Schlumberger, Martin ;

Tori, Masayuki ;

Sugitani, Iwao .

[3] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J].

Brose, Marcia S. ;

Nutting, Christopher M. ;

Jarzab, Barbara ;

Elisei, Rossella ;

Siena, Salvatore ;

Bastholt, Lars ;

de la Fouchardiere, Christelle ;

Pacini, Furio ;

Paschke, Ralf ;

Shong, Young Kee ;

Sherman, Steven I. ;

Smit, Johannes W. A. ;

Chung, John ;

Kappeler, Christian ;

Pena, Carol ;

Molnar, Istvan ;

Schlumberger, Martin J. .

LANCET, 2014, 384 (9940) :319-328

[4] Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer [J].

Capdevila, Jaume ;

Newbold, Kate ;

Licitra, Lisa ;

Popovtzer, Axon ;

Moreso, Francesc ;

Zamorano, Jose ;

Kreissl, Michael ;

Aller, Javier ;

Grande, Enrique .

CANCER TREATMENT REVIEWS, 2018, 69 :164-176

[5] Targeted therapies in advanced differentiated thyroid cancer [J].

Carneiro, Raquel M. ;

Carneiro, Benedito A. ;

Agulnik, Mark ;

Kopp, Peter A. ;

Giles, Francis J. .

CANCER TREATMENT REVIEWS, 2015, 41 (08) :690-698

[6] The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases [J].

Desar, Ingrid M. E. ;

Mulder, Sasja F. ;

Stillebroer, Alexander B. ;

van Spronsen, Dick-Johan ;

van der Graaf, Winette T. A. ;

Mulders, Peter F. A. ;

van Herpen, Carla M. L. .

ACTA ONCOLOGICA, 2009, 48 (06) :927-931

[7] Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies [J].

Duffy, Austin ;

Wilkerson, Julia ;

Greten, Tim F. .

HEPATOLOGY, 2013, 57 (03) :1068-1077

[8] Side effects of anti-angiogenic drugs [J].

Elice, Francesca ;

Rodeghiero, Francesco .

THROMBOSIS RESEARCH, 2012, 129 :S50-S53

[9] Role of angiogenesis in tumor growth and metastasis [J].

Folkman, J .

SEMINARS IN ONCOLOGY, 2002, 29 (06) :15-18

[10] Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients [J].

Gruber, Joshua J. ;

Colevas, A. Dimitrios .

ONCOLOGIST, 2015, 20 (02) :113-126

← 1 2 3 →